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Abstract
Background: Pancreatic cancer is a rapidly progressive disease which is often only amenable to
palliative treatment. Few patients respond to palliative chemotherapy, so surrogate markers indicating
which patients are likely to respond to treatment are required. There is a well-established link between
pro-inflammatory circulating cytokines and growth factors (CAF), and the development of neoplasia.
Agents that may modulate these factors are of interest in developing potential novel therapeutic
applications.
Methods: As part of a single-arm phase II trial in patients with advanced pancreatic cancer (APC) treated
with gemcitabine and intravenous (i.v.) omega-3 rich lipid emulsion (n-3FA), serum samples were analysed
for 14 CAF using a multiplex cytokine array. Baseline serum concentrations were correlated with overall
(OS) and progression-free survival (PFS), and changes in concentration correlated with time and out-
comes for CAF responders were analysed.
Results: Platelet-derived growth factor (PDGF) and fibroblast growth factor (FGF) concentrations
reduced significantly with treatment over time. Low baseline interleukin (IL)-6 and -8 were correlated
with improved OS. PDGF responders showed a tendency towards improved OS and FGF responders
a significantly improved PFS.
Discussion: Treatment with gemcitabine plus i.v. n-3FA may reduce concentrations of CAF
which may be associated with an improved outcome. Baseline IL-6 and -8 may be surrogate markers for
outcome in patients with APC treated with this regimen.
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Introduction
Pancreatic cancer is a rapidly progressive disease with a poor
outcome: 80% of patients have surgically unresectable disease at
presentation with a median survival of 6–12 months even with the
best available palliative chemotherapy regimens.1,2 Clearly novel
agents which can target specific pathways in tumour progression
are indicated together with biomarkers which can identify those
patients who will respond to treatment. There is a clear associa-
tion between angiogenesis and the development of most human
solid tumours, evidenced by data showing increased serum con-
centrations of pro-angiogenic factors such as vascular endothelial
growth factor (VEGF), platelet-derived growth factor (PDGF),
transforming growth factor-beta (TGF-b), epidermal growth
factor (EGF) and fibroblast growth factor (FGF) in these
patients.3–6 VEGF inhibition as an anti-angiogenic strategy for the
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treatment of solid tumours gained particular interest as a result of
overexpression and its correlation with a poor outcome.7,8 This
was reinforced by an improved outcome compared with standard
treatment in late phase randomized clinical trials using agents
which target receptors for these factors, such as bevacizumab
(VEGF-A: colorectal and lung), cetuximab (EGF: colorectal, head
and neck cancer) and erlotinib (EGF: lung cancer). However,
when applied to pancreatic cancer in randomized clinical trials,
most of these strategies have proven to have no clinical benefit.9,10
Only erlotinib was shown to have an overall survival (OS) benefit,
and although statistically significant, this has not translated into
widespread use as the clinical difference was marginal at best (10
days OS improvement over gemcitabine alone).11 This may be
because of the fact that pancreatic cancers are not highly vascular
tumours, and that they usually have a dense stromal reaction
around the tumour which may protect neoplastic cells from
targeted agents. Studies examining changes in pro-angiogenic
cytokines and growth factors (CAF) in advanced pancreatic
cancer (APC) patients have shown significantly increased expres-
sion of PDGF, VEGF and EGF compared with healthy controls.12
High concentrations of VEGF have been shown to be related to
poor outcome in previous studies of patients with APC.13–15
The role of PDGF in neoplasia is less clear. PDGF-BB stimulation
may enhance invasiveness in pre-clinical cell line models.16 There
may be a synergistic role for PDGF and VEGF in tumourigenesis,
with PDGF blockade potentiating the anti-neoplastic action of
VEGF blockade in cell lines.17 PDGF expression is correlated with
a poor clinical outcome in gastric cancer and osteosarcoma
patients.18,19
In pre-clinical experiments and clinical trials, omega-3 fatty
acids (n-3FA) have been shown to be able to modulate CAFs and
therefore have an anti-angiogenic potential.20,21 They are rapidly
incorporated into cell membrane phospholipid bilayers by com-
petition with omega-6 fatty acids. Cyclo-oxygenase-2 acting on
n-3FA produces metabolites which are far less pro-inflammatory
and pro-angiogenic than their n-6FA related counterparts. These
metabolites downregulate transcription of pro-angiogenic growth
factors and n-3FA has been shown to reduce expression of PDGF
both in vivo and in randomized clinical trials using healthy
volunteers.22
Methods
Patients with locally advanced or metastatic pancreatic cancer not
suitable for surgical resection but eligible for gemcitabine chemo-
therapy were enrolled in a single-arm phase II clinical trial (clini-
caltrials.gov registration NCT01019382). All patients were of
Eastern Cooperative Oncology Group (ECOG) performance
status 0 or 1 and none had undergone any prior chemotherapy
treatment for any reason. Patients underwent treatment with
gemcitabine (1000 mg/m3, Gemzar®; Eli Lilly Co., Indianapolis,
IN, USA) immediately followed by intravenous (i.v.) n-3FA-rich
lipid emulsion (up to 100 g, Lipidem®, B Braun, Melsungen,
Germany) weekly for 3 weeks followed by a rest week. This was
continued until tumour progression, subject death or withdrawal.
As part of this trial, which had clinical primary outcome meas-
ures, baseline concentrations and changes in serum CAFs were
evaluated and correlated with clinical outcome.
Whole blood was taken from the patients immediately prior to
treatment each week to minimize transient changes associated
with chemotherapy. This was transferred to a serum gel tube
which was centrifuged within 30 min at 1500 g for 15 min at 4°C.
The serum was transferred to Eppendorf tubes and stored at
-80°C. At the time of analysis, the serum was thawed and subject
to cytokine concentration quantification using a multiplex
cytokine array (Aushon biosystems).
The following pro-inflammatory and pro-angiogenic cytokines
were evaluated in the multiplex array: interleukin-1 beta (IL-1b),
tumour necrosis factor-alpha (TNF-a), IL-6 and -8, interferon
gamma (IFN-g) VEGF-A, VEGF-C and VEGF-D, Tumour necrosis
factor alpha-related apoptosis inducing ligand (TRAIL), Receptor
activator of nuclear factor kappa beta ligand (RANKL), PDGF,
hepatocyte growth factor (HGF), FGF and EGF.
The serum was thawed on ice and pipetted into the plate in
duplicate. The serum samples were run neat either in a 1:2 or a
1:4 dilution depending on the expected concentration of factors
to be detected and the dynamic range of the array. The standards
were made up in duplicate and the appropriate dilutions trans-
ferred to the plate. Once all the wells were filled with either
standards (first 16 wells) or serum samples (next 80 wells), the
plate was gently agitated for 1 h using an automated plate shaker.
The plate was then thoroughly washed manually using Aushon
custom wash, and biotinylated antibody added to each well. This
was then agitated again for 30 min and washed manually three
times. Streptavadin-horseradish peroxidase conjugate was then
added to each well and the plate agitated for 30 min and washed
three times. Finally a luminal-based substrate was added and the
plate read within 2 min in the custom-built CCD camera image
detector. Aushon Searchlight software was used to capture and
analyse the image to provide a concentration in each well of each
sample to be analysed compared with the standards. The con-
centrations were then entered into an Excel spreadsheet to
provide data on changes with treatment and time for each
patient. The changes over time in the logarithms of the concen-
trations of each factor were modelled using a random coeffi-
cients model fitted using xtmixed in STATA software. This model
fits a linear regression in which both the intercept and the slope
are allowed to vary randomly between individuals. In order to
define CAF responders, those patients who had a > 30% decrease
in CAF concentration during the treatment were defined as
responders for that particular CAF. Patients were divided into
either high or low expressors of CAFs at baseline around the
median. Kaplan–Meir survival curves were constructed using
Graphpad software to analyse OS and progression-free survival
(PFS) relationships with baseline cytokine concentrations and
cytokine responders.
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Results
Thirty-two patients were assessable for baseline cytokine concen-
trations having completed at least one treatment, with 25 assess-
able for cytokine response having completed at least 3 treatments
(Table 1).
High expressors of IL-6 and IL-8 had significantly shorter
median OS than low expressors (IL-6: 3.05 versus 7.0 months,
P = 0.009, IL-8: 3.05 versus 7.3 months, P = 0.02; Figs 1 and 2).
High expressors of IL-8 had significantly shorter PFS than low
expressors (2.8 versus 5.6 months, P = 0.002). High expressors of
IL-6 had a tendency to shorter PFS than low expressors (2.8 versus
5.3 months, P = 0.06). No other factors had any significant differ-
ences in survival between low or high expressors at baseline.
There was a significant reduction in PDGF (P = 0.05) and FGF
(P = 0.03) concentrations with treatment over time using the
statistical model (Figs 3 and 4). When analysed on a per-cycle
basis rather than across all cycles of treatment as a whole, a PDGF
concentration reduction was highly significant for each cycle.
Patients who were responders for PDGF had a tendency to
improved OS compared with non-responders (7.0 versus 5.4
months: log-rank P = 0.07; Fig. 5). Patients who were responders
for FGF had a significantly improved PFS compared with non-
responders (5.25 versus 1.3 months: log-rank P < 0.001; Fig. 6).
Discussion
While other studies have evaluated baseline CAF in patients with
APC and correlated concentrations with clinical outcomes, this
study is the first to the authors’ knowledge to evaluate changes in
CAF with treatment over time. In addition, this is the first study to
evaluate the use of an i.v. n-3FA rich lipid emulsion in combina-
tion with gemcitabine in APC patients. Regardless of the treat-
ment course, IL-6 and IL-8 seemed to be predictive biomarkers for
clinical outcome in this cohort. Both cytokines are highly associ-
ated with inflammation, and this could represent a highly acti-
vated inflammatory state in these patients which could be a
surrogate marker for infection or highly active neoplastic prolif-
eration. Nevertheless, if this is born out in larger scale clinical
Figure 1 High baseline interleukin (IL)-6 concentration predicts poor
overall survival (OS) (3.05 versus 7.0 months, P = 0.009)
Figure 2 High baseline interleukin (IL)-8 concentration predicts poor
overall survival (OS) (3.05 versus 7.3 months, P = 0.020)
Figure 3 Reduction in serum platelet-derived growth factor (PDGF)
concentration with time using a statistical model output (P = 0.05)
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trials, then these CAF could provide a marker of non-response to
treatment which could influence whether or not to begin treat-
ment on those patients in whom the potential benefit was deemed
be marginal. In addition, the reduction in PDGF in particular is
interesting, particularly when viewed in the context of the loss of
benefit during the rest week. The fact that differences in survival
between PDGF responders and non-responders did not quite
reach significance may be because the small numbers of patients
involved.
Limitations
There are some obvious limitations to this study. It is not clear
whether the effects observed are truly a result of the treatment
or if they are surrogate markers for the cohort of patients
who would have had a favourable outcome irrespective of any
manipulation. It is possible that the PDGF response is a marker
of treatment response and therefore clinical benefit or is inde-
pendent of treatment. In addition, this was a small non-
randomized single arm trial, so it is impossible to ascertain the
independent effect of n-3FA when added to gemcitabine and
whether some property of the combination is responsible for the
effect. A large-scale randomized controlled trial is planned to
assess the independent effects, with both clinical and transla-
tional science outcome measures.
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